Clinical Trial Aims to Test Tolerability of Felodipine in HD - Rare Disease Advisor
A phase 2 clinical trial, FELL-HD, tests felodipine's tolerability in Huntington disease (HD) patients, aiming to recruit 18 genetically confirmed HD patients aged 35-70 with early clinical features. Participants are given varying doses of felodipine over 58 weeks, followed by a 4-week follow-up, with the primary outcome being the number of adverse events. Additional measures include quality-of-life scales, cognitive and motor function, nonmotor symptoms, and disease biomarkers assessed through MRI. Blood and cerebrospinal fluid samples will also be analyzed. Felodipine, an approved hypertension drug, has shown strong autophagy-inducing effects in preclinical HD models.
Reference News
A phase 2 clinical trial, FELL-HD, tests felodipine's tolerability in Huntington disease (HD) patients, aiming to recruit 18 genetically confirmed HD patients aged 35-70 with early clinical features. Participants are given varying doses of felodipine over 58 weeks, followed by a 4-week follow-up, with the primary outcome being the number of adverse events. Additional measures include quality-of-life scales, cognitive and motor function, nonmotor symptoms, and disease biomarkers assessed through MRI. Blood and cerebrospinal fluid samples will also be analyzed. Felodipine, an approved hypertension drug, has shown strong autophagy-inducing effects in preclinical HD models.